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Student’s role 
This project was completed between August 2015 and January 2016 with the Biostatistics 
and Databases Program at the Kirby Institute, UNSW Australia.  
This project utilized observational data on HIV-positive patients that was previously 
collected for the TREAT Asia HIV Observational Databases Low Intensity Transfer 
(TAHOD-LITE). The study objective was to evaluate the predictors associated with CD4 cell 
count changes from combination antiretroviral treatment initiation for those who had sought 
care in 2010-13. The intention was to determine whether certain treatment related and 
demographic factors could contribute to improved CD4 cell count restoration. This was a 
useful preliminary analysis for a subsequent research studies. 
I completed this project independently and sought statistical advice from my supervisor, 
Matthew Law, when required. My tasks included concept development, data management 
and extraction, creating STATA and SAS programs for statistical analyses and writing of the 
report.  
Reflections on Learning 
Communication Skills 
This project was helpful in developing my communication skills between internal and 
external staff as well as concisely and clearly communicating the clinical significance and 
relevance of the project findings. Prior to the analysis, I discussed the project objectives, use 
of the data and whether the findings would be published with staff within my department as 
well as with staff from the clinical sites in the Asia-Pacific region that provided the data. 
This project challenged me to clearly communicate statistical results that were reflective of 
the accuracy and reliability of the models produced. Additionally, I had to ensure that the 
findings could be easily translated into a clinically meaningful conclusion.  
Work Planning 
Prior to this project, I had completed two studies that utilized TAHOD-LITE data and, as 
such, much of the data collection and literature review was complete. As I was involved with 
most of the data transfer for the patient database, I was aware of the strengths and limitations 
of the data which allowed me to develop a feasible concept proposal. Once complete, the 
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concept proposal was approved by Dr Patrick Kelly, the unit coordinator, and the principal 
investigators from each of the clinical sites. After approval, I began to retrieve the patients 
that satisfied the eligibility criteria for the study and begin the analysis. The initial results 
were discussed with my statistics supervisor and approved to allow me to subsequently write 
the report.  
Statistical Principles, Methods & Computing 
This project examined the predictors of the mean CD4 cell count at 12 months from 
combination antiretroviral treatment initiation with the use of a multivariate linear regression 
model. Further, it required me to check the model assumptions were met and that the model 
provided a reasonable fit of the data.  
Several units in the BCA program assisted me in completing this project, mainly being linear 
models and regression (LMR) and, data management and statistical computing (DMC). All of 
the analysis was completed in STATA v14 and SAS v9.4 programs. This experience taught 
me the importance of keeping organised and consistent file records to allow me to easily 
move between steps in the analysis.   
Teamwork 
My role as a student with the Biostatistics and Databases Program requires me to collaborate 
with several staff within the program but also with a collaborative network of clinical sites 
and a coordinating center site in the Asia-Pacific region. In the initial stages of this project, I 
communicated with the network to inform and agree on the concept for this project. 
However, during the statistical analysis, I worked independently on my project and consulted 
with my statistics supervisor, Matthew Law, when required.   
Ethical Considerations 
All ethical approvals for the data used from TAHOD-LITE had previously been obtained 
from Institutional Review Boards (IRBs) at each participating clinical site, the University of 
New South Wales, and the coordinating center at TREAT Asia/amfAR. Written informed 
consent for the collection of patient data was not obtained unless required by the site-specific 
IRBs. 
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Introduction 
The introduction of combination antiretroviral treatment (ART) has had substantial impact on 
the human immunodeficiency virus (HIV) epidemic [1, 2]. Patients responding to ART have 
reduced HIV viral replication and lower rates of HIV-associated morbidity, mortality and 
AIDS-related events [3-5]. Recommendations on when to initiate ART is largely based upon 
the CD4 T lymphocyte cell count [6-10]. The CD4 T lymphocyte cell is generally regarded as 
an indicator of immune deficiency and used as a prognostic marker of HIV disease 
progression [11-13].  
Early World Health Organisation (WHO) guidelines recommended ART initiation when 
patients were at an advanced stage of HIV or in asymptomatic stages of HIV with a CD4 cell 
count below 200cells/µL [6]. However, recent research has suggested that initiating ART at 
higher CD4 cell count levels has greater benefits in preventing further disease progression, 
further HIV transmission and reduced occurrence of opportunistic infections [14-17]. 
Although ideal, earlier ART initiation has been difficult to implement, particularly in low-
income or resource-limited countries, as it requires patients to access health care facilities to 
receive HIV testing and diagnosis at early stages of disease progression [18, 19]. 
The Asia Pacific region retains a heavy burden of the HIV epidemic, with close to 5 million 
people living with HIV in 2013 [20, 21]. Despite an increasing push towards earlier initiation 
of ART, barriers to receiving care have contributed to the inability of many HIV-positive 
patients, within the Asia-Pacific region, to be diagnosed and initiate ART at higher CD4 cell 
count levels [22, 23]. In 2012, UNAIDS estimates for the Asia-Pacific region indicated that 
the number of people accessing ART has increased yet, the treatment coverage rate remains 
lower than the global average at 51% and a majority of people living with HIV are not 
diagnosed [21]. Patients presenting with CD4 cell counts <200 cells/µL require longer 
periods of time to fully restore CD4 cell count levels which increases there susceptibility to 
treatment failure and death [23]. Other factors, such as previous exposure to mono/duo 
therapy and older age, are also known to hinder CD4 restoration [24, 25]. 
The study objective is to examine the CD4 cell count response to first-line ART among HIV-
positive patients from the TREAT Asia HIV Observational database low intensity transfer 
(TAHOD-LITE). Factors associated with mean CD4 cell count at 12 months will also be 
evaluated. Study findings will be useful for guiding decision making in future programs 
addressing the HIV-epidemic in the Asia-Pacific region. 
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Methods 
Data collection and Participants 
The TREAT Asia HIV Observational database (TAHOD) is a collaboration of 21 HIV 
treatment clinics across the Asia-Pacific region. TAHOD collects detailed data on a subset of 
HIV-positive patients that present at the clinics. The TREAT Asia HIV Observational 
database Low Intensity Transfer (TAHOD-LITE) is a sub-study of TAHOD and currently 
involves eight clinical sites from the Asia-Pacific region, including Cambodia, Hong Kong, 
India, Indonesia, Singapore and Vietnam. TAHOD-LITE collects data on all patients that are 
seen at the clinical site from a certain time point and, to date, includes over 30 000 adult HIV-
positive patients. TAHOD-LITE began collecting retrospective data in 2014 with most sites 
contributing patient data from 2003 through to May 2014. Some sites could only contribute 
data from the following years: 2006 (Singapore); 2004 (Cambodia); 2010 (Vietnam).  
Patient data includes: demographics (most recent clinic visit, gender, date of birth, mode of 
HIV exposure, HIV diagnosis date, date of death and death reason); hepatitis serology (HBV 
surface antigen test result and date, and HCV antibody test result and date); HIV-related 
biomarkers (CD4 and CD8 T lymphocyte counts, HIV viral load counts and date of results); 
ART history (antiretroviral drugs undertaken, and dates when initiated and ceased).   
Patient data is routinely collected in clinical care, and then anonymized before being 
electronically transferred to the Kirby Institute. Ethical approvals for TAHOD-LITE were 
obtained from Institutional Review Boards (IRB) at each of the clinical sites, the University 
of New South Wales and the coordinating center at TREAT Asia/amfAR. Written informed 
consent for collection of study data is not obtained unless required by the site-specific IRBs. 
First-line ART initiation is considered as the first combination regimen consisting of three or 
more ARV drugs. This analysis included all patients who had initiated a first-line ART 
regimen from 01 January 2010 to 31 December 2013, aged ≥18 years at first clinic visit and 
had at least one subsequent clinic visit after ART initiation. The primary endpoint was CD4 
cell count at 12 months from ART initiation. The secondary endpoints include the patient 
demographics at ART initiation and the CD4 cell count every 6 months from ART initiation 
up to 24 months. 
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Statistical methods 
There were three main objectives. The first objective was to summarize the patient 
demographics by country and overall. The second objective was to describe the median CD4 
cell count up to 24 months from ART initiation for each country and overall. The third 
objective was to identify the predictors that were associated with CD4 cell count at 12 
months from ART initiation. 
First, descriptive statistics were used to summarize the patient demographics by country and 
overall, including age at ART initiation, sex, mode of HIV exposure, pre-ART CD4 cell 
count and pre-ART HIV viral load, first-line ART regimen, previous mono/dual therapy, 
HBV and HCV co-infection ever. The pre-ART CD4 cell count and pre-ART HIV viral load 
was defined as the CD4 cell count or HIV viral load closest to, and within 6 months prior to, 
first-line ART initiation.  
Second, the median CD4 cell count, with interquartile range, was determined every 6 months, 
up to 24 months, from first-line ART initiation for each country and overall. The CD4 cell 
count at a given time point was defined as the CD4 cell count closest to, and within 3 +/- 
months of, the given time point. 
Third, linear regression models were used to examine the predictors associated with CD4 cell 
count at 12 months from ART initiation, adjusted for clinical site. In this approach, the 
regression model is fitted as: 
?̂?𝑖 = 𝛽0 + 𝛽1𝑋𝑖 + 𝛽2𝑍𝑖 + ∑ 𝛽𝑗𝑊𝑖
𝑝
𝑗=3
+ 𝜀𝑖 
Where ?̂?𝑖 is the predicted CD4 cell count at 12 months from ART initiation, 𝑋𝑖 is the pre-
ART CD4 cell count, 𝑍𝑖 is the dummy variable that indexes the eight clinical sites and 𝛽𝑗 is 
the subsequent coefficient estimates for the remaining p covariates included in the final 
regression model. The random error, 𝜀𝑖, are assumed to be independently and identically 
distributed with a normal distribution of mean zero and variance 𝜎2 [26]. Under this model, 
the slope intercept is allowed to vary for each of the clinical sites, while sharing the same 
slope.  
Several assumptions were required to be met to use linear regression model appropriately. 
These included: 
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1. Linear relationship between the baseline and follow-up CD4 cell counts. 
2. Linear relationship between follow-up CD4 cell counts and continuous predictors. 
3. No interaction between the baseline variable and grouping variable (that is, clinical 
site). 
4. Normality of error distribution and constant, linear error variance. 
5. Limited collinearity. 
The predictors, chosen a priori, included all the patient demographic variables previously 
mentioned. Prior to model selection, the association between the predictors and the CD4 cell 
count at 12 months was explored. Scatterplots with lowess curves superimposed were used to 
examine the linear association between the outcome, CD4 cell count at 12 months, and the 
continuous predictors. Categorical predictors were explored with the use of dot plots. 
Initially, linear regression models were performed for each of the predictors, adjusting for 
clinical site and pre-ART CD4 cell count. Only those covariates that were significantly 
associated with the outcome in these models were subsequently selected for the first 
multivariate model.   
Assessing collinearity 
Added variable plots and the variance inflation factor (VIF) were used to evaluate collinearity 
between the covariates in the first-order multivariate model. Added variable plots are 
graphical displays that allow us to investigate the partial correlation between the outcome and 
a given covariate, while adjusting for other covariates [27]. The VIF is a measure of how 
much of the variance of the ith independent variable is not related to the other independent 
variables. The VIF is given by: 1 (1 − 𝑅𝑖
2)⁄  where  𝑅𝑖
2 represents the squared multiple 
correlation for the regression of the ith independent variable on the other independent 
variables. In general, larger VIF values indicate the presence of collinearity issues [28].  
Assessing highly influential data points 
Influential points were evaluated to ensure that the model provided a good fit of the data. We 
used leverage and delta-beta statistic (DFBETA) values to assess the presence of influential 
points that would impact upon the regression model fit. The leverage ℎ𝑖𝑖, is the diagonal 
elements of the hat matrix, H. H is given by:  
𝐇 = 𝐗(𝐗′𝐗)−1𝐗′ 
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Where 𝐗 is the covariate matrix containing 𝑋𝑖𝑘 elements with i indicating the case and j 
indicating the covariate. The leverage is a measure of the distance between the X value for 
the ith observation and the mean X value for all n observations [29]. A high leverage does not 
necessarily mean that the data point will be influential to the coefficient estimates. By 
plotting the leverage against the squared normalized residuals we are able to evaluate outliers 
that have the potential to affect the fit of the model.  The ith squared normalized residual is 
given by: 
𝑎𝑖
2 =
𝑒𝑖
√𝐞T𝐞
 
Where 𝑒𝑖 the ith residual (𝑒𝑖 = 𝑌𝑖 − ?̂?𝑖), and 𝐞 is the residual matrix with 𝐞 = (𝐈 − 𝐇)𝐘 [29, 
30]. 
The DFBETA is given by: 
𝐷𝐹𝐵𝐸𝑇𝐴𝑖 =
𝑏1 − 𝑏1(−𝑖)
𝑠(𝑏1)
 
Where 𝑏1 is the estimated slope coefficient for all observations, 𝑏1(−𝑖) is the estimated slope 
coefficient when observation i is omitted and 𝑠(𝑏1) is the estimated standard error of the 
estimated slope coefficient for all observations [31]. The DFBETA value indicates the degree 
to which the estimated slope would change if observation i were omitted. 
Final model selection 
The final multivariate model was selected using a backwards stepwise approach to reduce the 
model to a set of statistically significant (2p < 0.05) covariates. The backwards stepwise 
selection process begins with all the potential predictors included in the model and obtaining 
the p-value results for each of the predictors. If any predictor has a p-value above the pre-
specified threshold, then they are removed from the model until a reduced model is produced. 
Previously removed predictors are then re-added to the reduced model, one step at a time, to 
verify that the predictor still produces a p-value below the given threshold [29, 32]. 
A normal probability plot was used to evaluate the normality of the residuals in the final 
multivariate model. The residuals were also plotted by the predicted values to assess the 
constancy and linearity of the residual variance as well as to identify any potential outlying 
points.  
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All statistical analyses were performed using Stata version 14 (Stata Corporation, College 
Station, Texas, USA) and SAS/STAT software (Version 9.4 of the SAS system for 
Windows). 
Results 
Patient characteristics 
A total of 7976 patients had initiated an ART regimen between 1st January 2010 and 31
st
 
December 2013. Subsequently, 136 patients were excluded as they were aged <18 years. The 
remaining 7840 patients had at least one subsequent clinic visit after ART initiation and were 
eligible to be included in the analysis.  
Overall, the majority of patients were male (66%) and had heterosexual contact as the mode 
of HIV exposure (73%). The median age at ART initiation was 36 years (Interquartile Range, 
IQR: 30-43). A majority of patients had not received a HIV viral load test prior to ART 
initiation (72%), while most had received a CD4 cell count prior to ART initiation (86%). 
Approximately 94% of patients had initiated a first-line ART regimen consisting of 
nucleoside reverse transcriptase inhibitors (NRTIs) and a nonnucleoside reverse transcriptase 
inhibitor (NNRTI) and about 2% had previous mono/dual therapy (Table 1). By country 
analysis showed some differences in patient demographics (Appendix 1). 
Table 1. Summary of patient characteristics at ART initiation. 
  n (%) 
Total 7840   
Age at ART initiation (years)     
≤30 2,087 (27) 
31-40 3,343 (43) 
41-50 1,555 (20) 
51+ 855 (11) 
Median [IQR] 36 [30, 43] 
Sex     
Male 5,183 (66) 
Female 2,657 (34) 
Mode of HIV Exposure     
Heterosexual contact 5748 (73) 
Homosexual contact 784 (10) 
Injecting drug use 571 (7) 
Other/Unknown 737 (9) 
Pre-ART HIV viral load (copies/mL)     
≤100000 1073 (14) 
>100000 1154 (15) 
Not tested 5613 (72) 
Median [IQR] 110 564 [30 563, 402 000] 
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Pre-ART CD4 cell count (cells/µL)     
≤50 1,620 (21) 
51-100 833 (11) 
101-200 1,307 (17) 
>200 2,983 (38) 
Not tested 1,097 (14) 
Median [IQR] 172 [53, 286] 
First ART regimen     
NRTI+NNRTI 7,381 (94) 
NRTI+PI 381 (5) 
Other 78 (1) 
Previous mono/dual therapy     
No 7,680 (98) 
Yes 160 (2) 
HBV Co-infection     
Negative 4,702 (60) 
Positive 473 (6) 
Not tested 2,665 (34) 
HCV Co-infection     
Negative 4,093 (52) 
Positive 776 (10) 
Not tested 2,971 (38) 
 
CD4 cell count response 24 months from ART initiation 
Of the 7840 patients, 1090 (14%) did not have a CD4 cell count within 6 months prior to 
ART initiation. Across all countries, there was an increasing trend in the median CD4 cell 
count from ART initiation, from 172 cells/µL (IQR: 53-286 cells/µL) at ART initiation to 
399 cells/µL (IQR: 252-546 cells/µL) at 24 months from ART initiation (Figure 1). This 
increasing trend was also present when stratified by country (Figure 2). Additionally, the 
number of patients receiving a CD4 cell count test every 6 months decreased as time from 
ART initiation increased.  
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Figure 1. Median CD4 cell count (cells/µL) from ART initiation, with interquartile range 
shown and total patients with CD4 tests at each time point. 
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Figure 2. Median CD4 cell count (cells/µL) from ART initiation by country, with 
interquartile range shown and total patients with CD4 tests at each time point. 
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Exploring linear association of predictors 
There were four continuous predictors selected to be potentially included in the linear 
regression model being age at ART initiation, CD4 cell count (cells/µL) at ART initiation and 
HIV viral load (copies/mL) at ART initiation. Initial scatterplots showed a clear linear 
association between the age (years) at ART initiation and the outcome, CD4 cell count at 12 
months as well as the CD4 cell count at ART initiation and the outcome (Figure 3A- Figure 
3B). The association between the outcome and HIV viral load at ART initiation was not 
monotonic or linear (Figure 3C).  Log transformation of the HIV viral load did not rectify to 
show a linear association with the outcome (Figure 3D). As a linear, monotonic association to 
the outcome could not be shown, HIV viral load at ART initiation was not selected for 
subsequent linear regression models. 
Figure 3. Scatterplot of the continuous covariates against the CD4 cell count at 12 months 
from ART initiation. (A) Age (years) at ART initiation. (B) CD4 cell count (cells/µL) at ART 
initiation. (C) HIV viral load (million copies/mL) at ART initiation. (D) HIV viral load (log10) 
copies/mL) at ART initiation. 
 
There were six categorical predictors selected to be potentially included in the linear 
regression model which were gender, HIV exposure group, previous mono/dual therapy, 
HBV co-infection, HCV co-infection and first ART regimen. The distributions for all the 
categorical variables showed a relatively normal distribution with most observations having a 
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CD4 cell count at 12 months ranging less than 1000 cells/µL (Figure 4A-Figure 4F). There 
was some skewing as there were some observations with a CD4 cell count greater than 1000 
cells/µL. However, the sizes of the groups are large enough to reasonably assume the 
normality assumption holds, even though the distributions appear to somewhat deviate from a 
normal distribution [33]. 
Figure 4. Dot plots of the CD4 cell count at 12 months from ART initiation for each of the 
categorical variables. (A) Gender. (B) HIV exposure group: hetero = heterosexual contact; 
homo = homosexual contact; IDU = injecting drug use. (C) Previous mono/dual therapy. (D) 
Hepatitis B co-infection (ever). (E) Hepatitis C co-infection (ever). (F) First ART regimen: 
NRTI= nucleoside reverse transcriptase inhibitor; NNRTI=nonnucleoside reverse 
transcriptase inhibitor; PI=protease inhibitor. 
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Univariate linear regression models 
All univariate models were adjusted for clinical site and CD4 cell count at ART initiation 
(per 100 cells/µL) and included all the predictors previously mentioned, except for HIV viral 
load at ART initiation. All univariate models were significantly associated with CD4 cell 
count at 12 months, except for HBV co-infection (p=0.220), first ART regimen (p=0.190) 
and previous mono/dual therapy (p=0.331) (Table 2).  Therefore, first multivariate linear 
regression model (Model 1) only included the significant predictors: age at ART initiation, 
gender, HIV exposure group, HCV co-infection and CD4 cell count at ART initiation. 
Clinical site was included in all univariate models to account for the patient differences that 
arise between the clinical sites. In the univariate model, adjusting for CD4 cell count at ART 
initiation, all coefficient estimates for each clinical site were significant, except for India (p 
value = 0.398). The mean change in CD4 cell count at 12 months from ART initiation for 
each site, with Hong Kong as the reference level, is given in Table 2. 
Table 2. Univariate models for outcome, CD4 cell count at 12 months from ART initiation, 
and respective covariates, adjusting for CD4 cell count at ART initiation and clinical site. 
  
Mean 
Diff. 
(95% CI) p value 
CD4 cell count at ART 
initiation (per 100 cells/µL)a 
89.1 (86.0, 92.2) <0.001 
Age (per 10 years)
b
 -11.5 (-16.1, -6.8) <0.001 
Female
b
 27.3 (16.9, 37.7) <0.001 
HIV exposure
b
   
 
<0.001
c
 
Heterosexual ref 
 
  
Homosexual 23.5 (6.3, 40.8) <0.001 
IDU -40.9 (-60.1, -21.8) <0.001 
Other -11.2 (-27.5, 5.1) 0.177 
HBV Co-infection (ever)
b
     0.220
c
 
Negative ref 
 
  
Positive -10.5 (-28.3, 7.4) 0.249 
Not tested -13.2 (-26.2, -0.1) 0.048 
HCV Co-infection (ever)
b
    
 
<0.001
c
 
Negative ref 
 
  
Positive -33.6 (-50.1, -17.2) <0.001 
Not tested -12.2 (-25.5, 1.0) 0.070 
First regimen
b
     0.190
c
 
NRTI+NNRTI ref 
 
  
NRTI+PI -7.4 (-30.1, 15.3) 0.524 
Other 37.7 (-9.3, 84.8) 0.116 
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Previous mono/dual therapy
b
 16.3 (-16.6, 49.3) 0.331 
Clinical site
b
      <0.001
c
 
Hong Kong ref 
 
  
South Korea 78.1 (47.5, 108.7) <0.001 
India 8.5 (-11.3, 28.3) 0.398 
Singapore -23.6 (-44.4, -2.8) 0.026 
Indonesia -28.3 (-54.3, -2.2) 0.033 
Cambodia -23.6 (-44.3, -2.9) 0.025 
Vietnam 1 -45.4 (-66.8, -24.0) <0.001 
Vietnam 2 -53.9 (-76.9, -30.8) <0.001 
                                                          
a
Adjusting for clinical site.   
b
Adjusting for CD4 cell count at ART initiation and clinical site.   
c
 Global p value from the Wald test for heterogeneity.   
 
Assessing collinearity in Model 1 
As expected, there was a very strong positive partial correlation between CD4 cell count at 
ART initiation and at 12 months from ART initiation (Figure 5A). There was also a good 
partial correlation between the outcome CD4 cell count and age (Figure 5B), and gender 
(Figure 5C). The partial correlation between the outcome CD4 cell count and the HIV 
exposure groups, and HCV co-infection was less prominent (Figure 5D-Figure 5G). The 
added variable plot clearly illustrates that once accounting for the other significant predictors, 
HIV exposure of IDU or other, and HCV co-infection have very little predictive association 
with the outcome CD4 cell count. Additionally, the VIF values also remained quite low for 
all the predictors suggesting that collinearity is not be an issue (Table 3). 
Table 3. VIF values for each of the predictors included in Model 1. 
Predictor VIF 1/VIF Predictor VIF 1/VIF 
CD4 cell count at ART initiation 
(cells/µL) 
1.15 0.87 Clinical site 
  
Age at ART initiation (years) 1.22 0.82 Hong Kong ref   
Female gender 1.40 0.71 South Korea 1.46 0.68 
HIV exposure group     India 2.60 0.39 
Heterosexual ref   Singapore 2.88 0.35 
Homosexual Contact 1.81 0.55 Indonesia 1.42 0.71 
IDU 1.88 0.53 Cambodia 3.43 0.29 
Other 1.16 0.86 Vietnam 1 3.70 0.27 
HCV co-infection 1.87 0.54 Vietnam 2 2.98 0.34 
Mean VIF 2.07 
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Figure 5. Added variable plots for the model 1 covariates, where the line represents the partial correlation of the CD4 cell count at 12 months 
(cells/µL) and the respective covariate. (A) CD4 cell count at ART initiation (cells/µL). (B) Age at ART initiation. (C) Female gender. (D) 
Homosexual contact HIV exposure. (E) Injecting Drug Use (IDU) HIV exposure. (F) Other HIV exposure. (G) Hepatitis C co-infection (ever). 
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Model selection 
As HCV co-infection was not significant in model 1, model 2 removed HCV co-infection as a 
predictor. In model 2, the coefficient estimate for HIV exposure of IDU changed from -22.1 
(95% CI: -45.2, 0.9) to -32.1 (95% CI: -51.8, -12.5) and, as such, became a significant 
predictor of the outcome (p value < 0.001). In model 3, HIV exposure was removed while 
HCV co-infection was included. The HCV positive co-infection coefficient estimates 
changed from -16.3 (95% CI: -35.9, 3.3) in model 1 to -27.2 (95% CI: -43.9, -10.6) in model 
3 which was significant (p value < 0.001) (Table 4).  
The significant changes in the coefficient estimates and, hence, the switching of significance 
suggests that there is collinearity between HCV co-infection and HIV exposure of IDU. 
Therefore, only one of the two can be selected for the final model. As HIV exposure also has 
heterosexual contact as a significant predictor of the outcome, it would be preferred as it 
contributes more to the final model than HCV co-infection would. As such, model 2 was 
selected and, subsequently, highly influential data points were evaluated.  
Figure 6. Leverage values for model 2 against the squared residuals, with lines indicating 
the mean leverage and mean squared residual. Patient IDs are also shown. 
 
Assessing highly influential data points in Model 2 
The mean leverage was 0.003 (standard deviation: 0.002), with a minimum value of 0.001 
and a maximum value of 0.015. Although the range of leverage values was quite large, the 
leverage plot clearly indicates that a majority of data points either had a higher than average 
leverage or a higher than average normalized residual squared value or some minor 
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combination of both (Figure 6). There were only two observations which were of concern as 
they had a combination of both extremely higher than average leverage and normalized 
residual squared (ID= 438 & 383). However, removal of these two observations had little 
impact on the coefficient estimates (Appendix 2).  
Most DFBETA values for each of the covariates in model 2 are within 0.2 and -0.2 (Figure 
7). Although there are a few observations outside of these limits, these are very few and not 
extremely large. The most extreme DFBETA value was -0.33 (DFBETA for age, ID = 1344) 
which indicates that the regression slope would increase by approximately 0.33 standard 
errors if this point was omitted. Overall, it is clear that this would have little impact on the 
coefficient estimates and clinical interpretation of the results. Hence, overall there is little 
evidence to suggest that there are any highly influential points that would produce a linear 
regression model with a poor fit of the data.  
Final model selection 
Model 1 displayed a collinearity issue between injecting drug user as mode of HIV exposure 
and HCV co-infection. Model 2 removed HCV co-infection as it had a weaker partial 
correlation to the outcome compared to mode of HIV exposure. Assessing the highly 
influential points in model 2 also showed little evidence to suggest the model was poorly fit.  
Interaction terms between the clinical sites and all other predictors were also evaluated in 
Model 2. The Wald test for heterogeneity indicated that all interaction terms were not 
significant between the clinical site and CD4 cell count at ART initiation (p value = 0.335), 
age at ART initiation (p value = 0.460), gender (p value = 0.241) and HIV exposure group (p 
value = 0.236).  
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Table 4. Results from the first, second and third models for the selection of the final multivariate model. 
  Model 1 Model 2 Model 3 
  
Mean 
Diff. 
(95% CI) p value 
Mean 
Diff. 
(95% CI) p value 
Mean 
Diff. 
(95% CI) p value 
CD4 cell count at ART 
initiation (per 100 cells/µL) 
86.7 (83.6, 89.9) <0.001 86.8 (83.7, 90.0) <0.001 87.0 (83.9, 90.2) <0.001 
Age (per 10 years) -8.9 (-13.7, -4.1) <0.001 -8.9 (-13.7, -4.1) <0.001 -10.1 (-14.8, -5.5) <0.001 
Female 21.5 (10.6, 32.5) <0.001 22.3 (11.4, 33.2) <0.001 20.8 (10.1, 31.5) <0.001 
HIV exposure     0.005     <0.001       
Heterosexual ref 
 
  ref 
 
        
Homosexual 20.8 (3.0, 38.7) 0.022 21.2 (3.4, 39.0) 0.020       
IDU -22.1 (-45.2, 0.9) 0.060 -32.1 (-51.8, -12.5) <0.001       
Other -11.3 (-27.5, 5.0)  0.175 -11.6 (-27.8, 4.7) 0.163       
HCV Co-infection (ever)    
0.102         
 
0.002 
Negative ref 
 
        ref 
 
  
Positive -16.3 (-35.9, 3.3) 0.103       -27.2 (-43.9, -10.6) <0.001 
Not tested -10.0 (-23.1, 3.2) 0.138       -10.8 (-24.0, 2.4) 0.107 
Clinical site                   
Hong Kong ref 
 
          ref 
 
          ref 
 
          
South Korea 83.8 (53.2, 114.5) <0.001 84.1 (53.4, 114.7) <0.001 78.2 (47.7, 108.6) <0.001 
India 16.4 (-7.1, 39.9) 0.170 10.6 (-11.6, 32.8) 0.348 6.3 (-15.1, 27.7) 0.562 
Singapore -18.6 (-39.4, 2.2) 0.079 -18.4 (-39.2, 2.3) 0.082 -20.8 (-41.4, -0.1) 0.049 
Indonesia -26.0 (-54.8, 2.8) 0.077 -31.4 (-59.2, -3.7) 0.026 -35.5 (-62.9, -8.1) 0.011 
Cambodia -24.7 (-48.0, -1.4) 0.038 -27.2 (-50.4, -4.0) 0.022 -34.3 (-55.5, -13.1) 0.002 
Vietnam 1 -38.2 (-62.6, -13.8) 0.002 -41.1 (-65.2, -17.1) 0.001 -50.0 (-72.5, -27.6) <0.001 
Vietnam 2 -43.6 (-69.7, -17.5) 0.001 -45.9 (-71.7, -20.0) 0.001 -56.6 (-80.6, -32.5) <0.001 
Constant 247.6 (216.2, 279.0) <0.001 246.4 (215.1, 277.8) <0.001 261.7 (234.1, 289.4) <0.001 
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Figure 7. The DFBETA values for each of the covariates in model 2. (A) CD4 cell count at ART initiation DFBETA values. (B) Age at ART 
initiation DFBETA values. (C) Gender DFBETA values. (D) Homosexual contact HIV exposure DFBETA values. (E) Injecting drug use HIV 
exposure DFBETA values. (F) Other HIV exposure DFBETA values. 
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Last, we evaluate the residuals in Model 2 to determine if they have constant variance and 
normally distributed. The normal probability residual plots for each of the countries indicate 
only minor deviations around the line of equality (Figure 8). The only indication of non-
normality is the heavy tails, shown quite prominently in Vietnam, Singapore, India and South 
Korea. However, this is only of slight concern and likely a result of the few extreme CD4 cell 
count values, those greater than 1000 cells/µL, that are generally uncommon. The residuals 
against the predicted values indicated a fairly constant and linear residual variance for all the 
countries (Figure 8). Hence, Model 2 satisfied the requirements of normally distributed, 
constant and linear residuals. 
The final multivariate model had the general structure for the mean CD4 cell count at 12 
months from ART initiation given by: 
?̂?𝒊 = 246.4 + 86.8 ×
Baseline CD4
100
 𝑖 − 8.9 ×
Age
10 𝑖
+ {
0 if MALE
22.3 if FEMALE
}
+ {
0 if EXPOSURE=1
21.2 if EXPOSURE=2
-32.1 if EXPOSURE=3
-11.6 if EXPOSURE=4
} + {
0 if SITE=1 -31.4 if SITE=5
84.1 if SITE=2 -27.2 if SITE=6
10.6 if SITE=3
-18.4 if SITE=4
-41.1 if SITE=7
-45.9 if SITE=8
} 
 
Where:  
?̂?𝒊  Mean CD4 cell count (cells/µL) predicted at 12 months from ART 
initiation 
Age: Age at ART initiation (years) 
Baseline CD4: CD4 cell count at ART initiation (cells/µL) 
Exposure: HIV exposure 
      1 = Heterosexual contact 
      2 = Homosexual contact 
      3 = Injecting Drug User 
      4 = Other 
Site: Clinical site 
      1 = Hong Kong 
      2 = South Korea 
      3 = India 
      4 = Singapore 
      5 = Indonesia 
      6 = Cambodia 
      7 = Vietnam 1 
      8 = Vietnam 2 
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Figure 8. The normal probability residual plots with the line of equality (left panel) and the 
residuals against the predicted values of the CD4 cell count at 12 months from ART 
initiation (right panel) in Model 2 for the patients in: (A) Hong Kong. (B) South Korea. (C) 
India. (D) Indonesia. (E) Singapore. (F) Vietnam. (G) Cambodia. 
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Figure 9 demonstrates the predicted CD4 cell count (cells/µL) at 12 months from ART 
initiation, with 95% confidence interval, from the final multivariate model for each of the 
clinical sites and by gender and CD4 cell count at ART initiation (cells/µL), assuming 
heterosexual contact as the HIV exposure and age at ART initiation of 37.9 years. Therefore, 
a female patient aged 37.9 years at ART initiation with heterosexual contact as HIV exposure 
attending the clinical site in Indonesia and initiating ART with a CD4 cell count of 
350cells/µL is predicted to have a CD4 cell count of 507cells/µL at 12 months from ART 
initiation. 
Figure 9. The adjusted predicted CD4 cell count at 12 months from Model 2, with 95% 
confidence intervals, assuming HIV exposure of heterosexual contact and mean age at 
ART initiation of 37.9 years for: (A) Females and (B) Males, by clinical site and CD4 cell 
count at ART initiation. 
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Discussion 
In this cohort of 7840 patients receiving care at 8 clinical sites in the Asia-Pacific region, 
predictors associated with the mean CD4 cell count at 12 months from ART initiation 
included age at ART initiation, gender and HIV mode of exposure, after controlling for CD4 
cell count at ART initiation and clinical site. The mean CD4 cell count at 12 months 
increased by 22.3 cells/µL (95% CI: 11.4 to 33.2 cells/µL) for females compared to males, by 
21.2 cells/µL (95% CI: 3.4 to 39.0 cells/µL) for those who had homosexual contact compared 
to heterosexual contact as mode of HIV exposure and by 86.8 cells/µL (95% CI: 83.7 to 90.0 
cells/µL) for every 100 cells/µL of CD4 cell count at ART initiation, adjusting for other 
significant predictors. While the mean CD4 cell count at 12 months decreased by 8.9 cells/µL 
(95% CI: -13.7 to -4.1 cells/µL) for every 10 years of age and by 32.1 cells/µL (95% CI: -
51.8 to -12.5 cells/µL) for those with injecting drug use compared to heterosexual contact as 
mode of HIV exposure, adjusting for other significant predictors. Also, the mean CD4 cell 
count at 12 months was influenced by the clinical site, after adjusting for other significant 
predictors, where, compared to Hong Kong, those who had attended South Korea had an 
increase of 84.1 cells/µL (95% CI: 53.4 to 114.7 cells/µL) while those who attended 
Indonesia, Cambodia and Vietnam (site 1 and 2) had a decrease of 31.4 cells/µL (95% CI: -
59.2 to -3.7 cells/µL), 27.2 (95% CI: -50.4 to -4.0 cells/µL), 41.1 cells/µL (95% CI: -65.2 to -
17.1 cells/µL) and 45.9 (95% CI: -71.7 to -20.0 cells/µL), respectively. 
The predictors associated with the CD4 cell count at 12 months are consistent with other 
studies for HIV-positive patients receiving ART. Older age in HIV-positive patients is 
associated with poorer outcomes to ART, including slower CD4 cell count restoration and 
higher risk of AIDS-related events [34]. It is postulated that the impaired CD4 cell count 
restoration is due to a decrease in thymic function [35]. We noted that the decrease in mean 
CD4 cell count at 12 months from ART was relatively quite small. For example, the expected 
CD4 cell count at 12 months would be reduced by 44.5 cells/µL (95% CI: -68.5 to -20.5) for 
a patient aged 50 years, controlling for other significant factors. However, during the first 
year on ART, CD4 cell count restoration is usually rapid and comparable between age groups 
[36]. Beyond that is the second phase of CD4 restoration, where older individuals are more 
likely to have reduced thymic output of naïve CD4 cells and reduced ability to produce 
mature CD4 cells, leading to poorer long-term CD4 restoration [37].  Therefore, the effect of 
age on expected CD4 cell count may have been greater if we had examined beyond 12 
months from ART initiation. 
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Previous studies have also reported injecting drug users as having a reduced CD4 cell count 
response to ART [25, 38]. Several factors may be contributing to their poorer response 
including decreased access to HIV care facilities and treatment [39, 40], more drug-related 
comorbidities [41, 42], poorer adherence to ART [43, 44] and more adverse drug-related 
events [45, 46]. Last, we found that females were associated with an increased mean CD4 cell 
count at 12 months from ART initiation, which is consistent with some other previous studies 
[47, 48]. Some possible explanations include females have better adherence [49, 50] or better 
overall health with fewer comorbidities [51]. However, there has been much recent research 
to suggest that females have a more optimal biological response to ART [52, 53].  
There are limitations to our study. Adherence to ART is critical to the effectiveness of ART 
in restoring CD4 and reducing HIV viral load [54]. We were unable to include adherence in 
our model as the patient database does not collect this information. HIV viral load and CD4 
cell count are both considered as strong prognostic markers of HIV disease progression [13, 
55]. The depletion of CD4 cell count is typically associated with an increase in HIV viral 
load [56]. We believe that the large proportion of patients without a HIV viral load test 
significantly contributed to the lack of linear association to CD4 cell count and hence, 
exclusion from the model. If these influencing factors had been included the model it may 
have accounted for more variability in the CD4 cell count at 12 months and allowed for more 
precise predictions.  
Our model assumes a constant mean change in the CD4 cell count at 12 months from ART 
initiation as the CD4 cell count at ART initiation varies. However, in practice, as the CD4 
cell count at ART initiation increases than the expected mean change in CD4 cell count at 12 
months from ART initiation decreases. That is, those initiating with a lower CD4 cell count 
have a greater mean change in CD4 cell count than those initiating with a higher CD4 cell 
count [57, 58]. Therefore, our model would not be suitable for accurately predicting the 
expected CD4 cell count at 12 months from ART initiation for those initiating ART with a 
CD4 cell count >500 cells/µL. Alternate models that would be more appropriate for 
predicting CD4 cell count change for those initiating at higher baseline CD4 cell count could 
include an additional quadratic term for baseline CD4 cell count or baseline CD4 cell count 
could be fitted as a categorical variable to allow for different estimates of the mean CD4 cell 
count change. 
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In addition, our study utilized data from several clinical sites in the Asia-Pacific region, 
mainly from different countries with distinct differences in economies and cultures. As most 
countries had only one contributing clinical site, there were many site-based differences 
including when the patients present for ART, the type of ART and the level of care that can 
be provided. Therefore, the model did include clinical site to account for the heterogeneity 
between the sites. The results were also heavily weighted by the Indian site which contributed 
38% of the patients. Despite this, the results were reasonably consistent among the clinical 
sites, showing a clear linear increasing trend in the CD4 cell count as the time from ART 
initiation increases. 
In conclusion, this analysis describes the CD4 cell count response from ART initiation for 
HIV-positive patients receiving care in the Asia-Pacific region. Our findings suggest that age 
at ART initiation, gender and HIV mode of exposure are all significant predictors of CD4 cell 
count at 12 months from ART initiation, adjusting for CD4 cell count at ART initiation and 
clinical site. Further advancements in more tolerable and efficient ART regimens, and patient 
management, including greater access to care and earlier initiation of ART, are likely to lead 
to faster CD4 cell count restoration. In addition, targeting vulnerable populations, such as 
injecting drug users, by improving access HIV care and retaining in care would improve 
treatment outcomes as well as reduce mortality and morbidity rates in this population [59]. 
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Appendix 1. Summary of patient characteristics at ART initiation, by country. 
  Hong Kong South Korea India Indonesia Singapore Vietnam Cambodia 
  n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Total 368   177   2965   725   1061   1611   933   
                              
Age at ART initiation                             
≤30 65 (18) 60 (34) 622 (21) 298 (41) 223 (21) 535 (33) 284 (31) 
31-40 127 (34) 52 (29) 1,386 (47) 290 (40) 305 (29) 798 (50) 385 (41) 
41-50 106 (29) 28 (16) 701 (24) 101 (14) 261 (24) 177 (11) 181 (19) 
51+ 70 (19) 37 (21) 256 (8) 36 (5) 272 (26) 101 (6) 83 (9) 
Median [IQR] 40 [33, 47] 37 [28, 47] 37 [32, 43] 32 [28, 38] 41 [32, 51] 33 [29, 38] 34 [30, 41] 
Sex                             
Male 306 (83) 164 (93) 1,864 (63) 452 (62) 986 (93) 1,009 (63) 402 (43) 
Female 62 (17) 13 (7) 1,101 (37) 273 (38) 75 (7) 602 (37) 531 (57) 
Mode of HIV Exposure                             
Heterosexual contact 116 (32) 44 (25) 2685 (91) 588 (81) 450 (42) 1014 (63) 851 (91) 
Homosexual contact 189 (51) 61 (34) 23 (1) 53 (7) 436 (41) 16 (1) 6 (1) 
Injecting drug use 8 (2) 1 (1) 9 (0) 48 (7) 30 (3) 471 (29) 4 (0) 
Other/Unknown 55 (15) 71 (40) 248 (8) 36 (5) 145 (14) 110 (7) 72 (8) 
Pre-ART HIV viral load (copies/mL)                             
≤100000 155 (42) 89 (50) 247 (8) 25 (3) 321 (30) 231 (15) 5 (1) 
>100000 196 (53) 75 (43) 254 (9) 34 (5) 348 (33) 247 (15) 0 (0) 
Not tested 17 (5) 13 (7) 2464 (83) 666 (92) 392 (37) 1133 (70) 928 (99) 
Median [IQR] 131165 
[37225, 
394145] 
83850 
[25800, 
526500] 
103377 
[19800, 
411914] 
157480 
[39500, 
518705] 
112641 
[32631, 
406000] 
111000 
[30500, 
370000] 
6392 
[269, 
18910] 
Pre-ART CD4 cell count (cells/µL)                             
≤50 93 (25) 25 (14) 275 (9) 259 (36) 238 (22) 557 (34) 173 (19) 
51-100 41 (11) 15 (9) 320 (11) 86 (12) 116 (11) 171 (11) 84 (9) 
101-200 47 (13) 38 (21) 584 (20) 88 (12) 146 (14) 256 (16) 148 (16) 
>200 174 (47) 86 (49) 1,203 (41) 128 (18) 506 (48) 415 (26) 471 (50) 
Not tested 13 (4) 13 (7) 583 (19) 164 (22) 55 (5) 212 (13) 57 (6) 
Median [IQR] 
196 
[46, 
319] 218 
[103, 
338] 203 
[101, 
290] 59 
[17, 
181] 202 
[54, 
315] 91 
[22, 
226] 218 
[71, 319] 
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First ART regimen                             
NRTI+NNRTI 268 (73) 59 (33) 2,845 (96) 720 (99) 966 (91) 1,606 (99) 917 (98) 
NRTI+PI 96 (26) 76 (43) 113 (4) 5 (1) 76 (7) 3 (<0.2) 12 (1) 
Other 4 (1) 42 (24) 7 (<0.3) 0 (0) 19 (2) 2 (<0.2) 4 (<0.5) 
Previous mono/dual therapy                             
No 366 (99) 176 (99) 2,879 (97) 719 (99) 1,045 (98) 1,578 (98) 917 (98) 
Yes 2 (1) 1 (1) 86 (3) 6 (1) 16 (2) 33 (2) 16 (2) 
HBV Co-infection                             
Negative 314 (85) 155 (88) 1,017 (34) 272 (37) 903 (86) 1,371 (85) 670 (72) 
Positive 36 (10) 7 (4) 55 (2) 21 (3) 79 (7) 216 (13) 59 (6) 
Not tested 18 (5) 15 (8) 1,893 (64) 432 (60) 79 (7) 24 (2) 204 (22) 
HCV Co-infection                             
Negative 330 (90) 156 (88) 792 (26) 248 (34) 953 (90) 957 (59) 657 (71) 
Positive 17 (4) 1 (1) 15 (1) 19 (3) 45 (4) 628 (39) 51 (5) 
Not tested 21 (6) 20 (11) 2,158 (73) 458 (63) 63 (6) 26 (2) 225 (24) 
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Appendix 2. Results from the second model when two potential highly influential points are removed. 
  
Model 2 
All observations 
Model 2  
Remove ID 438 
Model 2 
Remove ID 383 
Model 2 
Remove ID 438 & 383 
  
Mean 
Diff. 
(95% CI) 
p 
value 
Mean 
Diff. 
(95% CI) 
p 
value 
Mean 
Diff. 
(95% CI) 
p 
value 
Mean 
Diff. 
(95% CI) 
p 
value 
CD4 cell count at ART 
initiation (per 100 
cells/µL) 
86.8 (83.7, 90.0) <0.001 87.0 (83.8, 90.1) <0.001 86.8 (83.7, 89.9) <0.001 86.9 (83.8, 90.1) <0.001 
Age (per 10 years) -8.9 (-13.7, -4.1) <0.001 -9.6 (-14.4, -4.8) <0.001 -8.6 (-13.4, -3.8) <0.001 -9.2 (-14.0, -4.5) <0.001 
Female 22.3 (11.4, 33.2) <0.001 21.9 (11.1, 32.8) <0.001 22.4 (11.6, 33.3) <0.001 22.0 (11.2, 32.9) <0.001 
HIV exposure     <0.001                   
Heterosexual ref 
 
  ref 
 
  ref 
 
  ref 
 
  
Homosexual 21.2 (3.3, 39.0) 0.020 19.0 (1.2, 36.8) 0.036 19.9 (2.1, 37.7) 0.028 17.7 (0.0, 35.5) 0.050 
IDU -32.1 (-51.8, -12.5) 0.001 -32.3 (-51.9, -12.8) <0.001 -32.1 (-51.6, -12.5) <0.001 -32.3 (-51.8, -12.8) 0.001 
Other -11.6 (-27.8, 4.7) 0.163 -11.2 (-27.4, 5.0) 0.175 -11.0 (-27.2, 5.2) 0.184 -10.6 (-26.8, 5.5) 0.197 
Clinical site                         
Hong Kong ref 
 
  ref 
  
ref 
 
  ref 
 
  
South Korea 84.1 (53.4, 114.7) <0.001 77.6 (46.9, 108.2) <0.001 77.4 (46.8, 108.0) <0.001 70.8 (40.2, 101.4) <0.001 
India 10.6 (-11.6, 32.8) 0.348 9.3 (-12.8, 31.4) 0.409 10.1 (-12.0, 32.1) 0.372 8.7 (-13.3, 30.8) 0.436 
Singapore -18.4 (-39.2, 2.3) 0.082 -18.6 (-39.3, 2.1) 0.078 -18.6 (-39.3, 2.1) 0.078 -18.8 (-39.5, 1.8) 0.073 
Indonesia -31.4 (-59.2, -3.7) 0.026 -32.7 (-60.3, -5.0) 0.021 -31.8 (-59.4, -4.2) 0.024 -33.1 (-60.6, -5.5) 0.019 
Cambodia -27.2 (-50.4, -4.0) 0.022 -28.5 (-51.6, -5.4) 0.016 -27.7 (-50.8, -4.6) 0.019 -29.0 (-52.0, -6.0) 0.014 
Vietnam 1 -41.1 (-65.2, -17.1) 0.001 -42.5 (-66.4, -18.5) 0.001 -41.6 (-65.5, -17.7) 0.001 -42.9 (-66.8, -19.1) <0.001 
Vietnam 2 -45.9 (-71.7, -20.0) 0.001 -47.2 (-72.9, -21.4) <0.001 -46.3 (-72.0, -20.6) <0.001 -47.6 (-73.3, -22.0) <0.001 
Constant 246.4 (215.1, 277.8) <0.001 250.1 (218.8, 281.4) <0.001 245.7 (214.4, 276.9) <0.001 249.3 (218.2, 280.5) <0.001 
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